FY2024 EPS Estimates for agilon health Decreased by Analyst

agilon health, inc. (NYSE:AGLFree Report) – Leerink Partnrs decreased their FY2024 EPS estimates for shares of agilon health in a report issued on Monday, November 11th. Leerink Partnrs analyst W. Mayo now anticipates that the company will earn ($0.65) per share for the year, down from their previous forecast of ($0.35). The consensus estimate for agilon health’s current full-year earnings is ($0.43) per share. Leerink Partnrs also issued estimates for agilon health’s Q4 2024 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.39) EPS, FY2026 earnings at ($0.26) EPS, FY2027 earnings at ($0.18) EPS and FY2028 earnings at ($0.07) EPS.

A number of other analysts also recently issued reports on AGL. Benchmark reissued a “buy” rating and set a $9.00 price target on shares of agilon health in a report on Thursday, August 8th. Barclays reduced their target price on shares of agilon health from $5.00 to $2.00 and set an “underweight” rating for the company in a research report on Monday, November 11th. TD Cowen reduced their target price on shares of agilon health from $6.00 to $2.00 and set a “hold” rating for the company in a research report on Monday, November 11th. Citigroup cut their price objective on shares of agilon health from $2.50 to $1.75 and set a “sell” rating for the company in a research report on Wednesday. Finally, JMP Securities lowered shares of agilon health from an “outperform” rating to a “market perform” rating in a research note on Monday, November 11th. Three analysts have rated the stock with a sell rating, fifteen have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $6.38.

Read Our Latest Research Report on agilon health

agilon health Stock Down 7.3 %

AGL stock opened at $1.59 on Thursday. The firm’s fifty day simple moving average is $3.05 and its 200-day simple moving average is $4.86. agilon health has a 12 month low of $1.58 and a 12 month high of $13.76. The company has a market capitalization of $653.05 million, a P/E ratio of -1.69 and a beta of 0.60. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.29 and a quick ratio of 1.29.

agilon health (NYSE:AGLGet Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.19). The business had revenue of $1.45 billion during the quarter, compared to analysts’ expectations of $1.47 billion. agilon health had a negative net margin of 6.88% and a negative return on equity of 47.84%. During the same period last year, the company earned ($0.06) earnings per share.

Institutional Trading of agilon health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Barclays PLC grew its holdings in agilon health by 21.2% in the 3rd quarter. Barclays PLC now owns 1,228,952 shares of the company’s stock valued at $4,830,000 after buying an additional 214,830 shares during the period. XTX Topco Ltd raised its position in shares of agilon health by 271.1% in the 3rd quarter. XTX Topco Ltd now owns 119,747 shares of the company’s stock valued at $471,000 after purchasing an additional 87,481 shares in the last quarter. State Street Corp raised its position in shares of agilon health by 3.0% in the 3rd quarter. State Street Corp now owns 7,449,706 shares of the company’s stock valued at $29,277,000 after purchasing an additional 215,733 shares in the last quarter. Quadrature Capital Ltd acquired a new position in shares of agilon health in the 3rd quarter valued at approximately $261,000. Finally, Point72 DIFC Ltd acquired a new position in shares of agilon health in the 3rd quarter valued at approximately $99,000.

Insider Buying and Selling

In other agilon health news, CEO Steven Sell purchased 20,000 shares of the stock in a transaction on Thursday, September 12th. The stock was bought at an average price of $3.36 per share, for a total transaction of $67,200.00. Following the acquisition, the chief executive officer now directly owns 67,590 shares of the company’s stock, valued at $227,102.40. This represents a 42.03 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. 3.20% of the stock is currently owned by company insiders.

About agilon health

(Get Free Report)

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.

Recommended Stories

Earnings History and Estimates for agilon health (NYSE:AGL)

Receive News & Ratings for agilon health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for agilon health and related companies with MarketBeat.com's FREE daily email newsletter.